From 1 April 2015 dapagliflozin will be the first sodium–glucose co-transporter-2 (SGLT2) inhibitor to be PBS listed for type 2 diabetes add-on treatment in dual combination with insulin.
Four recent changes to PBS listings for sodium–glucose co-transporter-2 (SGLT2) inhibitors will impact on second- and third-line treatments for type 2 diabetes.
Many medicines are PBS listed for specialist prescribing only but, for some of these, GPs also need to be well informed. This issue of RADAR reviews two commonly prescribed ocular medicines, aflibercept (Eylea) and ranibizumab (Lucentis), used in the treatment of age-related macular degeneration, with an emphasis on factors of relevance for primary care health professionals.
Expanded PBAC recommendations for these anti-vascular endothelial growth factor (anti-VEGF) antibodies that inhibit ocular neovascularisation, improve oedema and maintain visual acuity.
From 1 August 2015 the calcimimetic therapy cinacalcet will be deleted from the list of drugs subsidised on the PBS
A full NPS RADAR review of aripiprazole oral was published in May 2004. This In Brief extends the evidence presented in that review to the new long-acting injection (LAI) formulation and compares safety and efficacy against oral aripiprazole and other LAI antipsychotics.